|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 18, 2017 ) According to the report Global Nuclear Medicine Radiopharmaceuticals Market, published by Market Data Forecast, The Global market has been estimated at USD 4500 million in 2015 and is projected to reach USD 8440 million by 2020, at a CAGR of 13.4% during the forecast period from 2015 to 2020.
Browse market data tables and in-depth TOC of the Global Nuclear Medicine Radiopharmaceuticals Market to 2020 @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/
Increasing incidence of cancer and cardiac ailments, immense technological advancements, increasing demand SPECT and PET applications and also the growing public awareness for healthcare are fuelling the market growth for Radio pharmaceuticals. Further, Integration of X ray tomography (CT) into SPECT has recently emerged as a excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory frame work which pose as a hurdle to translational research and clinical investigations and reimbursement issues are blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also restraining the global nuclear medicine Radioisotopes market.
Nuclear Medicine Radiopharmaceuticals Market: Segmentation
• By Type
o Diagnostic Radioisotopes
SPECT
• Technetium-99m
• Thallium-201
• Gallium-67
• Iodine-23
• Others
PET
• Fluorine-18
• Rubidium-82
• Others
o Therapeutic Radioisotopes
Beta Emitters
• Iodine-131
• Yttrium-90
• Samarium-153
• Rhenium-186
• Lutetium-177
Alpha Emitters
• Radium-223
Brachytherapy
• Cesium-131
• Iodine-125
• Palladium-103
• Iridium-192
• By Application
o Cardiology
o Lymphoma
o Thyroid
o Neurology
o Oncology
o Others
Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/request-sample
The market of radiopharmaceuticals is dominated by Diagnostic radioisotopes and Therapeutic radioisotopes. Diagnostic radioisotope market basically covers SPECT (Technetium-99m, Thallium-201 Gallium-67, Iodine) and PET (Fluorine-18, Rubidium-82) radioisotopes. Therapeutic radioisotopes cover Beta emitters (Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177), Alpha Emitters (Radium-223) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192). By application market is segmented into (cardiology, lymphoma, thyroid, neurology oncology, and others). Furthermore, based on geography the market is analyzed under various regions namely, North America, Europe, Latin America, Asia-Pacific and Middle-East & Africa.
Reasons to buy Nuclear Medicine Radiopharmaceuticals Market Report:
• Global, Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
• Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
• Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
• Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
• Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
• A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
• Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Avail Discount @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/request-discount
Based on market share estimation 90 % of the radiopharmaceuticals market is dominated by diagnostic radioisotopes while therapeutic radioisotopes contribute 10% of the market. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
North America is the dominant market for diagnostic radioisotopes. Within North America, US is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m. India and China hold a potential market for radioisotope due to rising healthcare and increasing demand for different radioisotopes in various treatments and applications.
Buy Now @ https://www.marketdataforecast.com/cart/buy-now/global-nuclear-medicine-radiopharmaceuticals-market-130
Some of the key players influencing the global nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p. A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering Global among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
